CSL Vifor Proposes Corrective Campaign to Resolve EU Antitrust Probe
CSL Vifor, EU Antitrust Probe, Corrective Campaign, Multi-Channel Communication, Competition
FDA Approves Takeda’s Subcutaneous Entyvio Injection for Maintenance Therapy in Moderate to Severe Crohn’s Disease
FDA, Takeda, Entyvio, Subcutaneous, Injection, Maintenance Therapy, Crohn’s Disease
Barinthus Bio’s HPV Immunotherapy Fails to Demonstrate Statistically Significant Efficacy in Early Study
Barinthus Bio, HPV immunotherapy, VTP-200, early study, underwhelming results, efficacy
AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline
AbbVie, Rinvoq, Immunology players, Physicians’ ranking, J&J drop, Humira, Crohn’s disease, FDA approval, JAK inhibitor
Roche’s Alecensa Gains FDA Approval for Postsurgical Early Lung Cancer Treatment
Roche, Alecensa, FDA approval, Postsurgical treatment, Early lung cancer
Sanofi Restructures US Commercial Vaccine Group Amid Cost-Saving Campaign
Sanofi, Restructuring, US Commercial Vaccine Group, Cost-Savings Campaign, Streamlined Strategic Sales Structure, Evolving Vaccine Market, Optimization for Efficiency and Effectiveness, Employee Support and Outplacement Assistance
Landmark Federal Data Privacy Proposal Unveiled
Federal Data Privacy, Public Showcase, Proposal, Consumer Rights, Privacy Law
Vertex’s Acquisition of Alpine Immune Sciences for Povetacicept: Humira-like Potential in IgAN, but Indication Variations Matter
Vertex, Alpine Immune Sciences, Povetacicept (ALPN-303), IgA nephropathy (IgAN), Humira-like potential, Multiple autoimmune diseases
Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC
Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines
Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce
Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer